Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
11:16am, Monday, 26'th Jun 2023
Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Is GSK a Strong Buy Right Now?
09:45am, Monday, 26'th Jun 2023
GSK has underperformed the broader markets and most of its big pharma peers over the last 10 years. With a tighter focus on branded pharma products, GSK arguably deserves another look by investors.
GSK settlement clears much if the the Zantac liability 'overhang', says US bank
09:19am, Monday, 26'th Jun 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s settlement with a California plaintiff over an alleged link between Zantac and cancer "clears 80%+ of the liability overhang", according to Jefferies. However, the US in
GSK: A Biopharma Giant On Sale
02:36am, Saturday, 24'th Jun 2023
GSK, or GlaxoSmithKline, has performed badly in the past decade, but its future outlook may not be as bleak. The company has spun off its consumer healthcare segment to focus on the vaccine and HIV se
GSK Settles Zantac Cancer Lawsuit Set to Go to Trial Next Month
04:30pm, Friday, 23'rd Jun 2023
American depositary receipts of GSK jumped after the U.K.-based biopharma company said it had reached a settlement in a lawsuit accusing the firm's discontinued heartburn medicine, Zantac, of causing
2 Stocks Defying Friday's Market Downturn
09:37am, Friday, 23'rd Jun 2023
Markets opened lower on Friday. CarMax reported weak financial results that were nevertheless better than most investors had expected.
GSK out-of-court deal encouraging but 'not the final full stop' in Zantac saga, say analysts
08:17am, Friday, 23'rd Jun 2023
GSK PLC (LSE:GSK, NYSE:GSK) making an out-of-court settlement for a case in California alleging its Zantac heartburn medication caused cancer, is "not a full stop" for the saga, say analysts. Paying
GSK Stock Climbs on Zantac Settlement
07:55am, Friday, 23'rd Jun 2023
GSK's settlement with a plaintiff in California over claims Zantac can cause cancer avoids a trial and brings it into line with industry peers.
There's a 'strong desire' in big pharma to continue to acquire, says JPMorgan analyst
07:15am, Friday, 23'rd Jun 2023
Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.
Virgin Galactic shares tumble, while Trupanian and GSK climb and other stocks on the move
05:41am, Friday, 23'rd Jun 2023
Shares of Trupanion Inc. TRUP, -5.73% jumped 16% in premaket trading after the pet-insurance provider announced that California and New York approved double-digit rate increases, saying that the hikes
GSK shares surge after reaching settlement on Zantac ahead of California trial
05:00am, Friday, 23'rd Jun 2023
GSK GSK shares surged 6% in London action as the U.K. pharmaceutical said it reached a settlement over its Zantac heartburn medication litigation with a plaintiff in California ahead of the trial slat
GSK shares up 3.4% after Zantac settlement
03:18am, Friday, 23'rd Jun 2023
Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose by 3.4% following the announcement of a confidential settlement reached by the UK pharmaceutical group concerning a US lawsuit. The case claimed that GSK's
GSK reaches settlement in U.S. Zantac litigation
02:13am, Friday, 23'rd Jun 2023
GSK Plc on Friday said it reached a confidential settlement of a litigation in the United States over claims that the British drugmaker's heartburn drug Zantac caused cancer.
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
02:06pm, Thursday, 22'nd Jun 2023
The CDC analysis suggests the shots will reduce the burden of RSV on hospitals in the fall.
GSK and Pfizer RSV jab gets US CDC backing
03:31am, Thursday, 22'nd Jun 2023
GSK PLC (LSE:GSK, NYSE:GSK) received a second dose of good this week that augers well for the roll-out of its respiratory syncytial virus (RSV) jab. An advisory committee to the US Centers for Diseas
